- Home
- OUST vs STRO Comparison
OUST vs STRO Comparison
Compare OUST & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | STRO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 85.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OUST | STRO |
|---|---|---|
| Price | $21.53 | $11.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $34.80 | $18.29 |
| AVG Volume (30 Days) | ★ 1.6M | 120.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,298,000.00 | $105,646,000.00 |
| Revenue This Year | $35.72 | $63.08 |
| Revenue Next Year | $35.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.20 | N/A |
| 52 Week Low | $6.34 | $5.23 |
| 52 Week High | $41.65 | $21.50 |
Technical Indicators
Market Signals| Indicator | OUST | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 79.96 |
| Support Level | $21.04 | $8.49 |
| Resistance Level | $23.61 | $12.00 |
| Average True Range (ATR) | 1.42 | 0.84 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 16.24 | 84.03 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.